Albumin/interferon alpha 2A fusion protein(Tianjin PuYing Biotechnology)

以标准剂量派罗欣（180μg/周）作为阳性对照，以慢性乙型肝炎患者为受试者，探索和评价多次皮下注射重组人血清白蛋白/干扰素α2a融合蛋白注射液后的耐受程度和安全性。同时研究该药在慢性乙型病毒性肝炎患者单次、多次给药后的药代动力学及初步的疗效，探索有效剂量，为II、III期临床试验制定安全、有效的给药方案提供依据。

This is an open label study that will be conducted at a single site in China to evaluate the safety,tolerability and PK/PD profile of multiple dose of recombinant human serum albumin/interferon alpha2a fusion protein in chronic hepatitis B patients.The total duration of study participation is up to 22 weeks for each subject,including 4 weeks screening period.